Iteos Therapeutics Stock Buy Hold or Sell Recommendation
| ITOS Stock | USD 7.32 0.13 1.81% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Iteos Therapeutics is 'Strong Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Iteos Therapeutics given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Iteos Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Iteos Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Iteos Stock please use our How to Invest in Iteos Therapeutics guide. Note, we conduct extensive research on individual companies such as Iteos and provide practical buy, sell, or hold advice based on investors' constraints. Iteos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
Iteos |
Execute Iteos Therapeutics Buy or Sell Advice
The Iteos recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Iteos Therapeutics. Macroaxis does not own or have any residual interests in Iteos Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Iteos Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Hold
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Iteos Therapeutics Trading Alerts and Improvement Suggestions
| Iteos Therapeutics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 35 M. Net Loss for the year was (134.41 M) with profit before overhead, payroll, taxes, and interest of 35 M. | |
| Iteos Therapeutics currently holds about 791.86 M in cash with (98.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 22.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Iteos Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Wall Street Analysts Think iTeos Therapeutics Could Surge 212.5 percent Read This Before Placing a Bet |
Iteos Therapeutics Returns Distribution Density
The distribution of Iteos Therapeutics' historical returns is an attempt to chart the uncertainty of Iteos Therapeutics' future price movements. The chart of the probability distribution of Iteos Therapeutics daily returns describes the distribution of returns around its average expected value. We use Iteos Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Iteos Therapeutics returns is essential to provide solid investment advice for Iteos Therapeutics.
| Mean Return | -0.16 | Value At Risk | -4.39 | Potential Upside | 4.55 | Standard Deviation | 2.57 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Iteos Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Iteos Stock Institutional Investors
The Iteos Therapeutics' institutional investors refer to entities that pool money to purchase Iteos Therapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 922.1 K | 683 Capital Management Llc | 2024-12-31 | 918.1 K | Vestal Point Capital Lp | 2024-12-31 | 900 K | Citigroup Inc | 2024-12-31 | 853.8 K | Renaissance Technologies Corp | 2024-12-31 | 837.2 K | Goldman Sachs Group Inc | 2024-12-31 | 730.5 K | Geode Capital Management, Llc | 2024-12-31 | 644.9 K | State Street Corp | 2024-12-31 | 585.9 K | Caption Management, Llc | 2024-12-31 | 509.8 K | Blackrock Inc | 2024-12-31 | 3.8 M | Boxer Capital Llc | 2024-09-30 | 2.9 M |
Iteos Therapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (5.0M) | 3.3M | (4.0M) | 2.4M | 2.7M | 2.9M | |
| Investments | (377K) | (1.2M) | (445.0M) | (434.0M) | (131.2M) | (137.7M) | |
| Change In Cash | 316.5M | 512.4M | (563.8M) | (33.6M) | (109.0M) | (103.6M) | |
| Free Cash Flow | (25.5M) | 512.0M | (112.1M) | (106.7M) | (99.8M) | (94.8M) | |
| Depreciation | 535K | 603K | 803K | 898K | 1.2M | 816.0K | |
| Other Non Cash Items | (35K) | 12K | (1.7M) | (7.2M) | (13.6M) | (12.9M) | |
| Capital Expenditures | 356K | 1.2M | 938K | 3.0M | 1.6M | 1.3M | |
| Net Income | (38.0M) | 214.5M | 96.7M | (112.6M) | (134.4M) | (127.7M) | |
| End Period Cash Flow | 336.5M | 848.8M | 285.0M | 251.5M | 142.4M | 135.3M | |
| Change To Netincome | (220K) | 3.0M | 13.8M | 21.6M | 24.8M | 26.0M |
Iteos Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Iteos Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Iteos Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Iteos stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.07 | |
β | Beta against Dow Jones | 0.91 | |
σ | Overall volatility | 2.56 | |
Ir | Information ratio | -0.02 |
Iteos Therapeutics Volatility Alert
Iteos Therapeutics exhibits very low volatility with skewness of 0.26 and kurtosis of 0.37. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Iteos Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Iteos Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Iteos Therapeutics Fundamentals Vs Peers
Comparing Iteos Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Iteos Therapeutics' direct or indirect competition across all of the common fundamentals between Iteos Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Iteos Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Iteos Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Iteos Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Iteos Therapeutics to competition |
| Fundamentals | Iteos Therapeutics | Peer Average |
| Return On Equity | -0.23 | -0.31 |
| Return On Asset | -0.14 | -0.14 |
| Operating Margin | (4.48) % | (5.51) % |
| Current Valuation | (210.16 M) | 16.62 B |
| Shares Outstanding | 38.19 M | 571.82 M |
| Shares Owned By Insiders | 1.10 % | 10.09 % |
| Shares Owned By Institutions | 91.18 % | 39.21 % |
| Number Of Shares Shorted | 1.58 M | 4.71 M |
| Price To Earning | 50.50 X | 28.72 X |
| Price To Book | 0.47 X | 9.51 X |
| Price To Sales | 7.99 X | 11.42 X |
| Revenue | 35 M | 9.43 B |
| Gross Profit | 35 M | 27.38 B |
| EBITDA | (153.09 M) | 3.9 B |
| Net Income | (134.41 M) | 570.98 M |
| Cash And Equivalents | 791.86 M | 2.7 B |
| Cash Per Share | 22.26 X | 5.01 X |
| Total Debt | 5.1 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 6.42 X | 2.16 X |
| Book Value Per Share | 16.14 X | 1.93 K |
| Cash Flow From Operations | (98.18 M) | 971.22 M |
| Short Ratio | 5.23 X | 4.00 X |
| Earnings Per Share | (3.32) X | 3.12 X |
| Target Price | 25.0 | |
| Number Of Employees | 173 | 18.84 K |
| Beta | 1.38 | -0.15 |
| Market Capitalization | 279.58 M | 19.03 B |
| Total Asset | 686.98 M | 29.47 B |
| Retained Earnings | (9.78 M) | 9.33 B |
| Working Capital | 469.18 M | 1.48 B |
| Net Asset | 686.98 M |
Note: Acquisition by Matthew Gall of 145000 shares of Iteos Therapeutics at 7.05 subject to Rule 16b-3 [view details]
Iteos Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Iteos . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Iteos Therapeutics Buy or Sell Advice
When is the right time to buy or sell Iteos Therapeutics? Buying financial instruments such as Iteos Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Iteos Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Materials ETFs Thematic Idea Now
Materials ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Materials ETFs theme has 54 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Materials ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Iteos Stock Analysis
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.